Trial Profile

A Double Blind, Randomized, Placebo-controlled Trial Evaluating the Efficacy and Safety of BI 1015550 Over at Least 52 Weeks in Patients With Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 26 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nerandomilast (Primary)
Indications Interstitial lung diseases
Focus Registrational; Therapeutic Use
Acronyms FIBRONEER™-ILD
Sponsors Boehringer Ingelheim; Boehringer Ingelheim GmbH International; Boehringer Ingelheim Pharma KG

19 May 2025 According to Boehringer Ingelheim Media Release, data from this trial published in the New England Journal of Medicine
19 May 2025 According to Boehringer Ingelheim Media Release, data from this trial presented as a late-breaking abstract at the American Thoracic Society (ATS) 2025 International Conference
19 May 2025 Results presented in the Boehringer Ingelheim Media Release

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com